Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WW domain-binding protein 2 is a transcriptional coactivator that binds to WW domain-containing proteins through its C-terminal PY motifs, particularly interacting with molecules like YAP, TAZ, estrogen, and progesterone receptors. It has a crucial role in oncogenic signaling, especially in breast cancer, by promoting the transcriptional activity of hormone receptors and Hippo pathway effectors. It is also essential for hearing, as mutations or loss of WBP2 result in progressive sensorineural hearing loss. WBP2's dual involvement in cancer progression and normal sensory signaling highlights its importance as a potential therapeutic target and biomarker for oncology and audiology applications[1][3][7][9].
Acts as a transcriptional coactivator enhancing the transactivation of estrogen and progesterone receptors by interacting via PY motifs with WW domain-containing proteins such as YAP and TAZ. Dysregulation can drive oncogenic signaling in breast and other cancers[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WW domain-binding protein 2 (WBP2).